Cipla Limited — Letrozole Exporter Profile
Indian Pharmaceutical Exporter · #1 for Letrozole · $4.1M export value · DGFT Verified
Cipla Limited is the #1 Indian exporter of Letrozole with $4.1M in export value and 82 verified shipments. Cipla Limited holds a 12.8% market share in Letrozole exports across 6 countries. The company exports 98 pharmaceutical products worth $1.1B across 26 therapeutic categories.
Cipla Limited — Letrozole Export Profile: Buyers & Destinations
Where Does Cipla Limited Export Letrozole?
| Country | Value | Shipments | Share |
|---|---|---|---|
| AUSTRALIA | $656.0K | 25 | 32.1% |
| THAILAND | $500.0K | 10 | 24.5% |
| CANADA | $362.7K | 11 | 17.7% |
| UNITED KINGDOM | $344.1K | 27 | 16.8% |
| BULGARIA | $120.3K | 7 | 5.9% |
| PAKISTAN | $61.0K | 2 | 3.0% |
Cipla Limited exports Letrozole to 6 countries. The largest destination is AUSTRALIA accounting for 32.1% of Cipla Limited's Letrozole shipments, followed by THAILAND (24.5%) and CANADA (17.7%). These destinations reflect Cipla Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Letrozole from Cipla Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| THE GOVERNMENT PHARMACEUTICAL | THAILAND | $500.0K | 10 |
| APOTEX AUSTRALIA | AUSTRALIA | $481.7K | 18 |
| PHARMASCIENCE INC .- | CANADA | $256.2K | 7 |
| ALLOGA UK LTD | UNITED KINGDOM | $204.7K | 18 |
| ALLOGA UK LIMITED | UNITED KINGDOM | $139.4K | 9 |
| MC PHARMA AD | BULGARIA | $120.3K | 7 |
| PHARMASCIENCE INC | CANADA | $106.5K | 4 |
| GENERIC HEALTH | AUSTRALIA | $74.0K | 3 |
| ARROW PHARMACEUTICALS PTY LTD | AUSTRALIA | $56.0K | 2 |
| JS BANK LTD, | PAKISTAN | $42.0K | 1 |
Cipla Limited supplies Letrozole to 13 buyers globally. The largest buyer is THE GOVERNMENT PHARMACEUTICAL (THAILAND), followed by APOTEX AUSTRALIA (AUSTRALIA) and PHARMASCIENCE INC .- (CANADA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Letrozole Export Value and How Much Does Cipla Limited Contribute?
India exported $18.6M worth of Letrozole through 2,112 shipments from 252 suppliers to 117 countries, serving 508 buyers globally. Cipla Limited contributes $4.1M to this total, accounting for 12.8% of India's Letrozole exports. Cipla Limited ships Letrozole to 6 countries through 13 buyers.
What Is the Average Shipment Value for Cipla Limited's Letrozole Exports?
Cipla Limited's average Letrozole shipment value is $50.0K per consignment, based on 82 shipments totaling $4.1M. The largest destination is AUSTRALIA (32.1% of Cipla Limited's Letrozole exports).
How Does Cipla Limited Compare to Other Indian Letrozole Exporters?
Cipla Limited ranks #1 among 252 Indian Letrozole exporters with a 12.8% market share. The top 3 exporters are INTAS PHARMACEUTICALS LIMITED ($6.9M), CIPLA LIMITED ($4.1M), SUN PHARMACEUTICAL INDUSTRIES LIMITED ($2.4M). Cipla Limited processed 82 shipments to 6 destination countries.
What Letrozole Formulations Does Cipla Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| LETROZOLE APOTEX 2.5 MG TABLETS (LETROZO | $234.1K | 9 |
| LETROZOLE 2.5MG TAB (25100PACKX3X10'S=753000NUM)NOS | $150.0K | 3 |
| LETROZOLE 2.5MG TAB (3x10'sX25200"PACK=756000NUM) | $150.0K | 3 |
| PMS - LETROZOLE 2.5 MG TABLETS (LETROZOLE 2.5MG) (INV.QTY.9200 PACK 3X10'S= 276000 NOS) | $150.0K | 3 |
| LETROZOLE NEO 2.5 MG TABLETS (LETROZOLE | $103.1K | 6 |
| PMS-LETROZOLE 2.5MG TABLETS (LETROZOLE 2.5MG)(PACKS QTY: 9040X30=271200 NOS) | $56.5K | 3 |
| PMS - LETROZOLE 2.5 MG TABLETS (LETROZOLE 2.5MG) (INV.QTY.8990 PACK 3X10'S=269700 NOS) | $56.2K | 3 |
| LETROZOLE WGR 2.5MG TABLETS (LETROZOLE2.5MG) ( INV QTY 18610 PACK 3 X 10'S = 558300 NOS) | $56.0K | 2 |
| PMS LETROZOLE 2 5MG TABLETS LETROZOLE 2 5MG 3X10S X9000 PACK 270000 NUM | $50.0K | 1 |
| LETROZOLE 2.5MG TAB (24,730 PACK X 3 X 10'S =741900 NOS) | $50.0K | 1 |
Cipla Limited exports 49 distinct Letrozole formulations including tablets, capsules, syrups, and combination drugs. The top formulation is LETROZOLE APOTEX 2.5 MG TABLETS (LETROZO with 9 shipments worth $234.1K.
Regulatory Requirements: Exporting Letrozole to Key Markets
What Cipla Limited must comply with to export Letrozole to its top destination countries
Australia — TGA
Approval Process
Registration on Australian Register of Therapeutic Goods (ARTG). Bioequivalence and quality data per TGA guidelines.
Timeline: 10–14 months
GMP & Export Requirements
TGA GMP clearance; PIC/S-aligned inspection. PIC/S certificate from India may expedite.
TGA sponsor licence for Australian importer; GMP clearance per manufacturing site
Note: TGA participates in PIC/S mutual recognition.
Canada — HC
Approval Process
ANDS (Abbreviated New Drug Submission) referencing Canadian Reference Product. Comparative bioavailability study required.
Timeline: 12–18 months
GMP & Export Requirements
Health Canada GMP (GUI-0001); Drug Establishment Licence (DEL) inspection
Drug Identification Number (DIN) for each product; Certificate of Pharmaceutical Product from CDSCO
Note: Subject to Good Import Practices and annual C.01.014.6 review.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Cipla Limited Compare to Nearest Letrozole Exporters?
Exporters ranked immediately above and below #1 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 2 | INTAS PHARMACEUTICALS LIMITED | $6.9M | 493 | 18 | $14.0K |
| 1 | CIPLA LIMITED ★ | $4.1M | 82 | 6 | $50.0K |
| 3 | SUN PHARMACEUTICAL INDUSTRIES LIMITED | $2.4M | 56 | 8 | $43.3K |
| 4 | EUGIA PHARMA SPECIALITIES LIMITED | $1.8M | 119 | 9 | $15.3K |
Cipla Limited ranks #1 among 252 Indian Letrozole exporters. Average shipment value of $50.0K compared to the market average of $74.0K. The closest competitors by value are INTAS PHARMACEUTICALS LIMITED and SUN PHARMACEUTICAL INDUSTRIES LIMITED.
Which Indian Ports Ship Letrozole Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 404 | 19.1% |
| SAHAR AIR CARGO ACC (INBOM4) | 393 | 18.6% |
| MUNDRA SEA (INMUN1) | 109 | 5.2% |
| AHEMDABAD AIR ACC (INAMD4) | 107 | 5.1% |
| MUNDRA SEA | 102 | 4.8% |
| DELHI AIR CARGO ACC (INDEL4) | 100 | 4.7% |
| Bombay Air | 99 | 4.7% |
| HYDERABAD AIR | 89 | 4.2% |
Geopolitical & Trade Policy Impact on Cipla Limited's Letrozole Exports
Cipla's export operations are currently navigating a complex geopolitical landscape. The Israel-Iran conflict has led to disruptions in Red Sea shipping routes, resulting in increased freight costs and extended transit times. These challenges are particularly acute for time-sensitive pharmaceutical shipments, necessitating strategic adjustments in logistics and supply chain management.
In the United States, recent import policies, including the imposition of 100% tariffs on branded or patented pharmaceutical products effective October 2025, have introduced additional hurdles for Indian exporters. While generic drugs, a significant component of Cipla's portfolio, may be less affected, the overall trade environment demands vigilance and adaptability. Conversely, the India-European Union Free Trade Agreement, concluded in January 2026, offers a promising avenue for Cipla. The agreement aims to eliminate tariffs on pharmaceuticals, potentially enhancing Cipla's competitiveness in the European market and offsetting challenges faced in other regions.
Cipla Limited — Regulatory Compliance & Quality Standards
Maintaining stringent quality standards is paramount for Cipla, given the diverse regulatory environments across its export markets. The company has demonstrated a strong commitment to compliance, as evidenced by the U.S. Food and Drug Administration's (FDA) classification of its Bengaluru facility as Voluntary Action Indicated (VAI) in October 2025. This classification is crucial for sustaining and expanding Cipla's presence in the U.S. market. Additionally, the European Union's evolving regulatory framework, including the Falsified Medicines Directive, necessitates continuous adaptation to ensure compliance and maintain market access.
About Cipla Limited
Cipla Limited exports 98 products worth $1.1B. Beyond Letrozole, top products include Fluticasone, Amlodipine, Salbutamol, Telmisartan, Salmeterol. View the complete Cipla Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Letrozole — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Letrozole shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Cipla Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 82 individual customs records matching Cipla Limited exporting Letrozole, covering 49 formulations to 6 countries via 13 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 117+ countries, 508+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Letrozole Export Data from Cipla Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Cipla Limited's Letrozole exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Cipla Limited
Full Company Profile →
98 products · $1.1B total trade · 26 categories
Letrozole Stats
Company Overview
Top Products by Cipla Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Cipla Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Letrozole. For current shipment-level data, contact TransData Nexus.